Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
- DOI
- 10.1080/13696998.2022.2081417
- Published
- 2022 Jan-Dec
- Container
- Journal of medical economics
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13696998.2022.2081417,
title = {Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.},
author = {Blauvelt A and Shi N and Murage MJ and Kern SA and Somani N and Burge R and Ridenour TL and Lew CR and Zimmerman NM and Zhu B},
year = {2022},
journal = {Journal of medical economics},
doi = {10.1080/13696998.2022.2081417},
url = {https://doi.org/10.1080/13696998.2022.2081417}
}RIS
TY - JOUR TI - Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings. AU - Blauvelt A AU - Shi N AU - Murage MJ AU - Kern SA AU - Somani N AU - Burge R AU - Ridenour TL AU - Lew CR AU - Zimmerman NM AU - Zhu B PY - 2022 JO - Journal of medical economics DO - 10.1080/13696998.2022.2081417 UR - https://doi.org/10.1080/13696998.2022.2081417 ER -
APA
A, B., N, S., MJ, M., SA, K., N, S., R, B., TL, R., CR, L., NM, Z., & B, Z. (2022). Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.. Journal of medical economics. https://doi.org/10.1080/13696998.2022.2081417
Source records
- pubmed · retrieved 2026-09-26T21:23:30.477Z
- europe-pmc · retrieved 2026-09-26T21:23:30.493Z